source
- AstraZeneca and Amgen’s Tezspire eyes Dupixent’s EoE stronghold after late-stage trial winAnalysts note that AstraZeneca and Amgen have secured a late‑stage trial win for Tezspire, positioning the drug as a possible challenger to Dupixent in eosinophilic esophagitis (EoE). Dupixent re…
- CAR T therapy moves from cancer to autoimmune disease, leveraging oncology safety lessonsCell therapy that transformed treatment of blood cancers is now being tested for autoimmune disorders, according to a recent opinion piece. Early cancer trials showed high complete response rates…